The therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils and its efficacy to attenuate inflammation in multiple sclerosis: A randomized, double-blind, placebo-controlled clinical trial phase I

J Neuroimmunol. 2022 Jan 15:362:577768. doi: 10.1016/j.jneuroim.2021.577768. Epub 2021 Nov 17.

Abstract

The aim of this study was to evaluate the therapeutic effect of PEGlated nanoliposome of pistachio unsaturated oils (PEGNLPUOs) and their efficacy to attenuate inflammation in multiple sclerosis (MS). This study was a randomized, double-blind, placebo-controlled clinical trial phase I. The level of docosahexaenoic and eicosapentaenoic acid was significantly increased and the level of matrix metallopeptidase-9 was significantly decreased in MS patients treated with PEGNLPUOs. The level of cytokine showed a Th2-biased response with attenuation of inflammation after treatment with PEGNLPUOs. The number of relapses, disability scores, and T2 lesions was significantly decreased after treatment with PEGNLPUOs.

Keywords: Inflammation; PEGlated nanoliposome; Pistachio unsaturated oils; Randomized clinical trial; Relapsing-remitting multiple sclerosis.

Publication types

  • Clinical Trial, Phase I
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Double-Blind Method
  • Fats, Unsaturated / administration & dosage
  • Female
  • Humans
  • Inflammation / drug therapy*
  • Inflammation / immunology
  • Inflammation / pathology
  • Liposomes
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Multiple Sclerosis, Relapsing-Remitting / pathology
  • Nanoparticle Drug Delivery System / therapeutic use*
  • Pistacia*
  • Plant Oils / administration & dosage*

Substances

  • Fats, Unsaturated
  • Liposomes
  • Nanoparticle Drug Delivery System
  • Plant Oils